Can I Take Resveratrol with Leqvio (Inclisiran)?

How Inclisiran Works and Why Its Interaction Profile Is Unusual

Inclisiran is a long-acting siRNA that silences hepatic PCSK9 synthesis. It does not block the protein after secretion. Instead, it binds PCSK9 messenger RNA inside liver cells and triggers its degradation, which frees LDL receptors to clear more LDL-C from circulation. The FDA prescribing information confirms inclisiran is not a substrate, inhibitor, or inducer of any CYP450 enzyme, P-glycoprotein, or major hepatic transporter.

siRNA delivery and hepatic uptake

The drug reaches liver cells via GalNAc (N-acetylgalactosamine) conjugation, which targets the asialoglycoprotein receptor on hepatocytes. After receptor-mediated endocytosis, inclisiran enters the RNA-induced silencing complex (RISC). This intracellular pathway has no overlap with cytochrome P450 enzymes. That biological fact is the single most important reason resveratrol's known CYP3A4 inhibition does not translate into a meaningful drug interaction here.

Plasma half-life and dosing implications

Inclisiran has a plasma half-life of roughly 9 hours, yet its gene-silencing effect persists for approximately 6 months because the RISC complex remains active in hepatocytes long after the parent drug has cleared. A 2020 pharmacokinetic analysis published in Clinical Pharmacokinetics confirmed that inclisiran's long pharmacodynamic duration is driven by intrahepatic RISC loading, not by sustained plasma exposure.

This pharmacokinetic profile matters because most supplement interactions occur at the level of intestinal or hepatic CYP enzymes during oral drug absorption. Inclisiran sidesteps that entirely.

What Resveratrol Does in the Body

Resveratrol (3,5,4'-trihydroxystilbene) is a stilbene polyphenol concentrated in red-grape skins, red wine, and Japanese knotweed (Polygonum cuspidatum). Most over-the-counter supplements contain 100 mg to 1,000 mg of trans-resveratrol per capsule.

Oral bioavailability and metabolism

Resveratrol absorbs rapidly but undergoes extensive first-pass glucuronidation and sulfation in the intestinal wall and liver. Absolute oral bioavailability is below 1% for the free form. A 2011 study in the Journal of Nutritional Biochemistry (N=40) measured peak plasma resveratrol concentrations under 100 ng/mL after a 500 mg oral dose, with rapid conversion to resveratrol-3-O-glucuronide and resveratrol-3-sulfate.

Despite low free-drug levels, metabolites circulate for several hours, and some retains biological activity in the intestinal mucosa and liver.

CYP enzyme effects

In vitro, resveratrol inhibits CYP3A4, CYP2C9, and CYP2D6. A 2009 pharmacokinetics study in Drug Metabolism and Disposition found that resveratrol at 1 g/day for 4 weeks produced modest CYP3A4 inhibition in healthy volunteers, raising midazolam AUC by approximately 17%. A 17% AUC increase is clinically meaningful for narrow-therapeutic-index drugs like warfarin or tacrolimus. For inclisiran, which has no CYP3A4 dependency, it is irrelevant.

Estrogenic and platelet effects

Resveratrol acts as a selective estrogen receptor modulator (SERM). At doses above 1 g/day it may weakly stimulate estrogen receptor alpha. Research published in the Journal of Clinical Endocrinology and Metabolism (2011, N=29 postmenopausal women) found that 1 g/day resveratrol for 12 weeks produced detectable estrogenic effects on vaginal cell maturation and estrone/estradiol ratios. Clinicians managing patients with hormone-sensitive conditions should note this, even though it has no bearing on inclisiran's lipid mechanism.

Resveratrol also inhibits thromboxane A2 synthesis and platelet aggregation in vitro. A meta-analysis in the British Journal of Nutrition (2016, 9 trials) found that resveratrol supplementation significantly reduced platelet aggregation compared with placebo (P<0.05). Patients on anticoagulants or antiplatelet agents already have an independent reason to disclose resveratrol use to their prescriber.

Direct Pharmacokinetic Interaction Between Resveratrol and Inclisiran

No randomized trial, observational study, or case report in the published literature documents a pharmacokinetic interaction between resveratrol and inclisiran. The absence of evidence here is mechanistically explained, not just empirically absent.

Why no CYP interaction occurs

Inclisiran's route of elimination avoids hepatic CYP oxidation entirely. After subcutaneous injection, approximately 13% of the dose is excreted renally as intact drug. The remainder is presumed degraded by endonucleases into short oligonucleotide fragments. The inclisiran FDA label lists no drug-drug interactions because nonclinical studies showed it was not a substrate or inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4.

Transporter considerations

Some siRNA molecules can interact with hepatic uptake transporters such as OATP1B1 and OATP1B3. The GalNAc conjugate on inclisiran facilitates receptor-mediated uptake through the asialoglycoprotein receptor rather than through OATP transporters, so the transporter-based interactions seen with statins (which are OATP substrates) do not apply. Resveratrol at typical supplement doses has not shown clinically meaningful OATP inhibition in human studies.

Interaction Classification for Inclisiran + Resveratrol

| Interaction Axis | Mechanism Present? | Clinical Significance | |---|---|---| | CYP3A4 inhibition by resveratrol | No impact on inclisiran | None | | P-gp inhibition by resveratrol | No impact on inclisiran | None | | OATP transporter competition | Not applicable to GalNAc-siRNA | None | | Pharmacodynamic LDL-C effects | Both may lower LDL-C (resveratrol weakly) | Additive, not adverse | | Platelet/anticoagulant effects | Resveratrol mild; inclisiran none | Relevant only if anticoagulants co-prescribed | | Estrogenic activity | Resveratrol at >1 g/day only | Monitor in hormone-sensitive patients |

Does Resveratrol Affect LDL-C on Its Own?

This question matters because patients sometimes ask whether adding resveratrol might boost the LDL-C reduction from inclisiran.

Clinical trial data on resveratrol and lipids

Resveratrol's lipid effects are modest and inconsistent in human trials. A 2016 systematic review and meta-analysis in the American Journal of Clinical Nutrition (22 RCTs, N=1,518) found that resveratrol supplementation did not significantly reduce LDL-C (mean difference: 0.02 mmol/L; 95% CI: -0.08 to 0.12; P=0.68) compared with placebo. HDL-C and triglycerides showed similarly null results.

Inclisiran's efficacy data are far more compelling. In ORION-10 (N=1,561, patients with ASCVD), inclisiran 284 mg every 6 months reduced LDL-C by 52.3% from baseline at Day 510 compared with a 0.5% reduction in the placebo group (P<0.001). The ORION-10 results were published in the New England Journal of Medicine in 2020. Resveratrol is unlikely to add measurable benefit on top of that magnitude of reduction.

PCSK9 and sirtuin pathways

Some researchers have proposed that resveratrol activates SIRT1 (sirtuin-1), which may modulate PCSK9 transcription. A 2015 study in Atherosclerosis found that resveratrol reduced hepatic PCSK9 expression in HepG2 cells by approximately 25% at a 50 µM concentration. Whether this in vitro finding translates to humans taking 100 to 500 mg oral supplements, especially given resveratrol's low bioavailability, remains unclear. Since inclisiran already silences PCSK9 mRNA by over 70%, any additional PCSK9 suppression from resveratrol would be redundant rather than additive.

Inclisiran's Safety Profile and Established Interactions

Knowing what does interact with inclisiran provides important context for what does not.

Adverse effects to monitor

The most common adverse event in ORION clinical trials was injection-site reactions, occurring in 2.6% to 8.2% of patients. The ORION-9 trial (N=482, patients with heterozygous familial hypercholesterolemia) reported injection-site reactions in 16.8% of the inclisiran group versus 1.9% placebo, though most were mild and transient. Systemic adverse events were similar between inclisiran and placebo.

No hepatotoxicity signal emerged in pooled ORION trial data. Liver function tests do not require routine monitoring per the FDA label, unless the patient has a pre-existing liver condition.

Drugs that do interact with inclisiran

Because inclisiran has no CYP or transporter-based interactions, its main interaction concern is theoretical interference with other antisense or siRNA therapies (additive off-target silencing). The FDA label carries no boxed warning for drug interactions. Patients taking statins, ezetimibe, bempedoic acid, or PCSK9 monoclonal antibodies (alirocumab, evolocumab) alongside inclisiran in clinical trials showed no pharmacokinetic interaction.

Practical Guidance for Patients Already Taking Both

Stopping resveratrol before an inclisiran injection is not required. No dose-separation window is clinically justified based on current evidence.

What to tell your prescriber

Disclose all supplements at every injection visit. While resveratrol does not affect inclisiran's mechanism, transparency allows the prescribing clinician to catch other interactions (for example, resveratrol plus warfarin, or resveratrol plus tamoxifen). The American Heart Association's 2023 dietary supplement advisory notes that patients should always inform their healthcare team of supplement use, because indirect interactions through other co-medications are common.

Dose thresholds worth tracking

Standard dietary resveratrol from red wine amounts to roughly 0.3 to 2 mg per 150 mL glass. Supplement capsules typically deliver 100 mg to 1,000 mg. The platelet-inhibition and estrogenic effects described above emerge primarily at doses above 500 mg to 1,000 mg daily. Patients taking cardiovascular doses of resveratrol (500 mg or more daily) should mention this specifically, particularly if they are also on aspirin, clopidogrel, or anticoagulants.

Monitoring schedule

The standard clinical schedule for inclisiran already includes lipid panels at each 6-month injection visit. No resveratrol-specific laboratory testing is warranted for most patients. If a patient is postmenopausal, has a hormone-sensitive condition, or takes anticoagulants, the prescribing clinician may choose to check estradiol or coagulation parameters at their discretion.

What the Guidelines Say About PCSK9 Inhibition and Supplement Use

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol endorses PCSK9 inhibitors as add-on therapy for patients who cannot reach LDL-C targets on maximally tolerated statin therapy. The ACC/AHA guideline states: "PCSK9 inhibitors are recommended (Class I, Level of Evidence A) for patients with clinical ASCVD who require additional LDL-C lowering after maximally tolerated statin and ezetimibe therapy." The guideline does not address resveratrol specifically, which reflects its absence from any meaningful drug-interaction database for PCSK9-targeted agents.

The 2022 American College of Cardiology Expert Consensus Decision Pathway for non-statin therapies adds that patient adherence to the injection schedule is the single largest modifiable determinant of LDL-C control with siRNA-based agents. Supplement use that does not affect efficacy should not become a distraction from that priority.

Special Populations

Patients with heterozygous familial hypercholesterolemia (HeFH)

Inclisiran is specifically approved for HeFH. These patients often have LDL-C above 190 mg/dL despite maximum statin therapy. ORION-9 (N=482) showed a 39.7% mean LDL-C reduction with inclisiran at Day 510 in HeFH patients. Adding resveratrol at standard doses will not meaningfully alter this trajectory, given the null lipid data in clinical trials. The interaction concern remains low-risk in this group.

Postmenopausal women

This subgroup deserves extra attention because resveratrol at high doses may weakly stimulate estrogen receptors. Women with a history of estrogen-receptor-positive breast cancer who are on aromatase inhibitors should consult their oncologist before taking resveratrol at doses above 250 mg daily, separate from any inclisiran consideration.

Patients with hepatic impairment

Inclisiran has not been studied in severe hepatic impairment (Child-Pugh C). Resveratrol undergoes heavy hepatic conjugation. In patients with moderate-to-severe liver disease, resveratrol bioavailability may increase unpredictably, and its CYP inhibition effects may become more pronounced. In this setting, co-administration of any supplement warrants clinical review.

Summary of Risk Classification

The resveratrol-inclisiran combination carries a low overall interaction risk based on mechanistic reasoning and the absence of documented clinical interaction data. Resveratrol does not inhibit the enzymes or transporters inclisiran depends on. At doses below 500 mg daily, resveratrol's CYP inhibition, platelet effects, and estrogenic activity are all subclinical in most patients. At doses above 1,000 mg daily, the platelet and estrogenic effects deserve consideration in susceptible patients, though these are independent of inclisiran's pharmacology.

Per the inclisiran prescribing information, LDL-C should be measured at least 30 days after each injection to confirm a treatment response. If LDL-C is not reaching target despite adherence to the every-6-month schedule, diet, co-medications, and supplement use should all be reviewed, not because resveratrol blunts inclisiran but to rule out other contributing factors.